Pfizer provided more details on berobenatide’s monthly dosing path for obesity, extending the dose schedule after weekly administration in its VESPER-3 mid-stage study. New data presented at the American Diabetes Association meeting indicated patients transitioning from weekly to monthly dosing continued losing weight through 28 weeks without reaching a plateau. Pfizer previously reported weight loss up to 12.1% in participants who stayed on treatment; the new presentation emphasized that weight-loss trajectory persisted after the weekly-to-monthly switch. Analysts and clinicians will still compare the magnitude and durability directly against weekly competitors such as Eli Lilly’s Zepbound. Pfizer’s continuing readouts also add momentum to the company’s broader Metsera bet, reinforcing interest in oral-to-injectable competition by dosing convenience and longer exposure profiles.